Back to Journals » Journal of Pain Research » Volume 5

Controlled release formulation of oxycodone in patients with moderate to severe chronic osteoarthritis: a critical review of the literature

Authors Taylor Jr. R, Raffa RB, Pergolizzi, Jr. J

Received 18 January 2012

Accepted for publication 6 March 2012

Published 23 April 2012 Volume 2012:5 Pages 77—87

DOI https://doi.org/10.2147/JPR.S21965

Review by Single-blind

Peer reviewer comments 3

Robert Taylor Jr1, Robert B Raffa2, Joseph V Pergolizzi Jr3–5
1NEMA Research Inc, Naples, FL; 2Department of Pharmaceutical Sciences, Temple University School of Pharmacy, Philadelphia, PA 3Department of Pharmacology, Temple University School of Medicine, Philadelphia, PA 4Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD; 5Department of Anesthesiology, Georgetown University School of Medicine, Washington, DC, USA

Abstract: Osteoarthritis (OA) is a physically and emotionally debilitating disease that predominantly affects the aging adult population. Current pharmacologic treatment options primarily consist of nonsteroidal anti-inflammatory drugs and/or acetaminophen, but associated side effects, analgesic limitations, especially in the elderly, and the need for around-the-clock analgesia have led physicians to search for alternative analgesics. Opioids have shown effectiveness at mitigating both chronic cancer and noncancer pain, and their ability to be placed into controlled release (CR) formulations suggests that they may prove efficacious for OA patients. One formulation, oxycodone CR, has shown effectiveness in cancer pain patients and in some trials of noncancer low back pain. In this review, the objective was to synthesize the reported findings by researchers in this field and present an up-to-date look at the efficacy, safety, and tolerability of oxycodone CR in OA patients. Public literature databases were searched using specific keywords (eg, oxycodone CR) for studies assessing the efficacy and safety profile of oxycodone CR and its use in patients with OA. A total of eleven articles that matched the criteria were identified, which included three placebo-controlled trials, six comparative trials, one pharmacokinetic study in the elderly, and one long-term safety trial. Analysis of the studies revealed that oxycodone CR is reasonably efficacious, safe, and tolerable when used to manage moderate to severe chronic OA pain, with similar side effects to that of other opioids.

Keywords: oxycodone, extended release, controlled release, opioid, osteoarthritis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

Peripherally acting μ-opioid receptor antagonists as treatment options for constipation in noncancer pain patients on chronic opioid therapy

Pergolizzi Jr JV, Raffa RB, Pappagallo M, Fleischer C, Pergolizzi, III J, Zampogna G, Duval E, Hishmeh J, LeQuang JA, Taylor R Jr

Patient Preference and Adherence 2017, 11:107-119

Published Date: 17 January 2017

Revisiting transdermal scopolamine for postoperative nausea and vomiting

Pergolizzi JV, Raffa RB, Zampogna G, Annabi HM, Pallaria TJ, Taylor R

Research and Reports in Transdermal Drug Delivery 2015, 4:35-44

Published Date: 13 August 2015

Tramadol/paracetamol fixed-dose combination in the treatment of moderate to severe pain

Pergolizzi Jr JV, van de Laar M, Langford R, Mellinghoff H-U, Morón Merchante I, Nalamachu S, O'Brien J, Perrot S, Raffa RB

Journal of Pain Research 2012, 5:327-346

Published Date: 29 August 2012

Readers of this article also read:

Emerging and future therapies for hemophilia

Carr ME, Tortella BJ

Journal of Blood Medicine 2015, 6:245-255

Published Date: 3 September 2015

Green synthesis of water-soluble nontoxic polymeric nanocomposites containing silver nanoparticles

Prozorova GF, Pozdnyakov AS, Kuznetsova NP, Korzhova SA, Emel’yanov AI, Ermakova TG, Fadeeva TV, Sosedova LM

International Journal of Nanomedicine 2014, 9:1883-1889

Published Date: 16 April 2014

Methacrylic-based nanogels for the pH-sensitive delivery of 5-Fluorouracil in the colon

Ashwanikumar N, Kumar NA, Nair SA, Kumar GS

International Journal of Nanomedicine 2012, 7:5769-5779

Published Date: 15 November 2012

A novel preparation method for silicone oil nanoemulsions and its application for coating hair with silicone

Hu Z, Liao M, Chen Y, Cai Y, Meng L, Liu Y, Lv N, Liu Z, Yuan W

International Journal of Nanomedicine 2012, 7:5719-5724

Published Date: 12 November 2012

Cross-linked acrylic hydrogel for the controlled delivery of hydrophobic drugs in cancer therapy

Deepa G, Thulasidasan AK, Anto RJ, Pillai JJ, Kumar GS

International Journal of Nanomedicine 2012, 7:4077-4088

Published Date: 27 July 2012

Crystallization after intravitreal ganciclovir injection

Pitipol Choopong, Nattaporn Tesavibul, Nattawut Rodanant

Clinical Ophthalmology 2010, 4:709-711

Published Date: 14 July 2010